Internationally, investment in the availability of routine healthcare data for improving health, health surveillance and healthcare is increasing. We assessed the validity of hospital episode data for identifying individuals with chronic kidney disease (CKD) compared to biochemistry data in a large population-based cohort, GLOMMS-II (n=70,435). GLOMMS-II links hospital episode data to biochemistry data for all adults in a health region with impaired kidney function and random samples of individuals with normal and unmeasured kidney function in 2003. We compared identification of individuals with CKD by hospital episode data (based on ICD-10 codes) to the reference standard of biochemistry data (at least two estimated glomerular filtration rates <60 ml/min/1.73m2 at least 90 days apart). Hospital episode data, compared to biochemistry data, identified a lower prevalence of CKD, had low sensitivity (<10%) but high specificity (>97%). Using routine health care data from multiple sources offers the best opportunity to identify individuals with CKD.
INTRODUCTION
Chronic kidney disease (CKD) has been identified as a worldwide public health problem with a rising incidence and prevalence 1 , and is associated with high morbidity (cardiovascular disease, need for renal replacement therapy (RRT)), mortality and health care costs ml/min/1.73m 2 alone (stage [3] [4] [5] , present for at least three months 1 . Estimates of prevalence, based on the first part of this definition, in the US suggest the prevalence of CKD stages 1-4 2 increased from 10.0% in 1988-1994 to 13.1% in 1999-2004. 3 However, other studies have reported varied prevalence rates of CKD (0.6% to 42.6). 4 In UK general practices only 2.9%
are registered as having CKD. 5 Part of the variation in prevalence estimates may be due to how CKD is defined and the data sources used to identify individuals with CKD.
For many conditions, information on disease prevalence is estimated from disease registries, GP registers and/or coding of hospital episodes. The use of hospital episode data (recorded in Scotland as the Scottish Morbidity Record (SMR) 01), either as single episodes or longitudinally linked episodes to identify comorbidities has been used extensively in research. 6 For acute events that almost exclusively require hospital admission (e.g. hip fracture) this may be a valid source of information. 7 . For chronic diseases such as CKD, hospital episode data may require supplementation from other sources of data to fully elucidate disease load, and facilitate early identification. The UK government and others internationally, have invested in routine health care data (ie funding opportunities, investment in digital health systems) since it is thought to be important for health and health care through research, health surveillance and health care planning. [8] [9] [10] [11] [12] For individuals with CKD, early detection and management is believed to be important to reduce morbidity and slow progression to RRT. 13 However, the forum of care may vary, with all patients requiring GP care and more advanced patients potentially requiring assessment by nephrology care. In the UK, there is no standard surveillance system for the identification of people with CKD. Ideally those with CKD would be identified clinically from a combination of sources including biochemistry testing for estimated GFR (eGFR) and albuminuria, however this relies on clinicians identifying and noting abnormal results and that these are 3 sustained abnormalities rather than an acute change. This is sometimes difficult to achieve in regions where biochemistry testing is done by multiple providers and where not all results are returned to a single clinician responsible for compiling results. An alternative means of identifying those with CKD would be to flag those that have routine hospital episode data consistent with this CKD diagnosis and subsequently informing GPs for follow-up and confirmation.
Two recent systematic reviews 14, 15 , and recent studies [16] [17] [18] [19] , have evaluated the degree to which administrative coding accurately identified individuals with kidney diseases, reporting a large variation in sensitivity (3%-88%). Only a few studies have compared hospital administrative data to laboratory data employing the 2002 KDOQI definition of stages [3] [4] [5] CKD, of at least two eGFR <60 ml/min/1.73m 2 at least 90 days apart. 18, 20, 21 Of these, only
Ronksley et al. 18 did so in a community cohort, in Canada. Using a community based population increases the generalisability of results as opposed to relying on, for example, a selected inpatient population. We did not identify any studies from the UK that compared hospital episode data to laboratory data.
With the growing emphasis on the use of routine administrative data, validation studies become increasingly important in order to provide information on the accuracy and validity of findings that are based exclusively on these data. As administrative data have the potential to be a rich source of data for population-based research in CKD, we aimed to assess the validity of diagnostic algorithms for CKD in hospital episode data compared to biochemistry data in a large population-based cohort in Grampian, Scotland.
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METHODS
We carried out a validation study within an existing cohort developed by data linkage of biochemistry, hospital episode and death registry data.
Study Population -Grampian Laboratory Outcomes, Morbidity and Mortality Study-II (GLOMMS-II) cohort
All inpatient, out-patient and community serum creatinine (isotope dilution mass spectrometry (IDMS) aligned) and urinary protein measurements in the Grampian region, Registry and local renal system). Where present, the first "low" eGFR <60 ml/min/ last eGFR prior to 90 days pre-index also being low i.e. between the start of the database records in 1999 and the index value. CKD stages 1 and 2 were defined as an index eGFR >60ml/min/1.73m 2 with microalbuminuria or macroalbuminuria on urine albumin or protein creatinine ratio (ACR or PCR) testing. Individuals were categorised as not having CKD if their index eGFR was not measured, was normal or was impaired but not CKD (at least one eGFR <60ml/min/1.73m 2 but with no evidence that this was sustained for at least three months).
Defining CKD from hospital episode data
In the UK, information about an episode of hospital care is recorded following a patient's discharge. In Scotland, this information is recorded in the SMR01, which is collated nationally by the Information Services Division (ISD), part of NHS National Services Scotland. SMR01 is an episode-based patient record relating to all inpatient and day case discharges. This information contributes to NHSScotland's Performance Assessment
Framework, clinical governance and performance indicators, and for planning and research purposes. 22 Diagnoses are coded using International Classification of Disease-10 (ICD-10) and procedures coded using the Office of Population Censuses and Surveys Classification of
Interventions and Procedures (OPCS). We defined CKD for each patient from hospital episode data for two time periods; 2003 (including admission at index) and also adding a five year "look-back" period. 6 To identify potentially relevant codes to define CKD, an experienced nephrologist reviewed all ICD-10 and OPCS codes. Three groups of codes (algorithms) were developed (Table 1): first, a broad definition encompassing most diseases which might include renal complications ("All codes"); second, an algorithm to define renal disease based on a Charlson comorbidity algorithm 23 ("renal disease"); and third, an algorithm highly likely to identify CKD ("chronic kidney disease"). 
Data linkage
The Community Health Index (CHI) number, a unique patient identifier used throughout the Scottish health care system, was used to link GLOMMS-II with hospital episode data using deterministic matching. Patient identifiers were removed after data linkage. The dataset was stored in the Grampian Data Safe Haven allowing secure controlled access for researchers while ensuring data security.
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The flow diagram for generating GLOMMS-II is shown in Figure 1 . From the database query 71,251 individuals were identified. There were 471 excluded from the analysis because of missing information on index date, duplication or death on index date. The 345 people already on RRT at index (thus end stage renal disease, not just CKD), were excluded from the analysis (74.8% had a "CKD" code from SMR01). Overall, 70,435 individuals were included in this study. The validity of hospital episode data-defined CKD within specific subgroups was considered, including CKD stage (stage 1-2, 3a, 3b, 4 and 5) and age (<75 or ≥75 years). To explore sensitivity further, analyses were repeated comparing hospital episode data to an alternative definition for biochemistry-defined CKD, which excluded those with impaired eGFR and those with eGFR not measured from the no-CKD definition. Analyses were performed using Stata version 13 28 and Microsoft Excel.
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RESULTS
A total of 70,435 individuals were included. The characteristics of the study population are shown in Table 2 . Based on biochemistry data, 28% (19, 694) As shown in Table 3 , based on the reference standard of biochemistry-defined CKD, 28%
(19,694) of the cohort had CKD stage 1-5. The proportion of the cohort identified with probable CKD by hospital episode data was substantially lower, ranging from 0.8% to 4.1% over the three coding algorithms and two time periods.
Hospital episode data identified CKD was generally less common compared to biochemistrydefined CKD, and varied across coding algorithms and time periods (Table 3 ). The sensitivity of hospital episode coding compared to biochemistry for identifying CKD was low, ranging from 2.2% to 8.6%. Specificity of coding was >97% for all coding algorithms and time periods. All algorithms improved by adding a five year look-back period in addition to just SMR01 records from 2003, showing higher sensitivities. The very inclusive "all codes" algorithm was most sensitive but least specific, followed by the "renal disease" and "chronic kidney disease" algorithm which was most specific. Overall the agreement between hospital episode data and biochemistry defined CKD was very poor (kappa values <0.1) because of low numbers identified with hospital episode data, despite excellent specificity.
Sensitivity analyses were carried out comparing hospital episode data to an alternative definition for biochemistry-defined CKD, excluding those with impaired eGFR and those with eGFR not measured from the no-CKD definition. However, this, as expected, only improved the PPV further and reduced the NPV further of hospital episode data. For those with CKD algorithm defined CKD using 2003 plus five year look-back data, PPV 99.56% (vs 81.06%) and NPV 51.05% (vs 72.68%).
Using the "renal disease" and "CKD" coding algorithms, since more specific, including the five-year look-back period, the performance within age and CKD stage subgroups was considered (Table 4) . Amongst those with biochemistry identified CKD, the "renal disease" algorithm identified similar but slightly more individuals than the "CKD" algorithm. Worse CKD stage was associated with better identification (sensitivity) using both hospital episode based algorithms (4.8% of stage 3b compared to 56.9% of stage 5 CKD, for the "CKD" algorithm). For biochemistry identified CKD stage 3b to 5, younger age (<75 vs ≥75 years) was associated with a higher sensitivity using the hospital episode recording algorithms.
13 Table 2 : Characteristics of study population CKD, chronic kidney disease; eGFR, glomerular filtration rate; IQR, interquartile range; PCR, proteincreatinine ratio; ACR, albumin-creatinine ratio Renal risk groups based on biochemistry data 
DISCUSSION
We used a large UK community cohort to demonstrate whether the use of coding algorithms to identify renal disease, in particular CKD, from hospital episode data was a useful alternative should biochemistry data be difficult to access. We found that hospital episode data coding algorithms were very specific for CKD, however sensitivities were very poor (at best only 8.6% identified), as was agreement. Of interest the proportion of those with CKD identified through biochemistry data who were also identified with hospital episode coding was higher at more advanced CKD stages and in those under 75 years of age.
CKD is recorded poorly in hospital episode data. This may be because CKD is often not the main reason for admission. This is likely to be similar for other chronic diseases such as diabetes and hypertension, unlike acute events such as hip fracture. Also, the recognition of CKD in the time prior to eGFR reporting (2008) was poor, and may have improved in the time since then. Those with more advanced renal disease are also more likely to be frequent in-patients as a result of the higher comorbidity load 30 and as a result of increased complications of their renal disease, thus the more likely that renal disease will be recognised during the admission episode coding.
Comparison with existing literature
Few studies 18, 20, 21 have validated hospital administrative data compared with a reference standard of biochemistry data employing the KDOQI definition of CKD, of at least two eGFR <60 ml/min/1.73m 2 at least 90 days apart, and none included CKD stage 1 and 2 (those with proteinuria). In keeping with our findings, where reported, sensitivities are low and specificities high for hospital episode data compared to biochemistry defined CKD. 14, 15, 18, 19 We also found high PPVs, which means that individuals who are identified as having CKD from hospital episode coding, do have CKD according to biochemistry data, thus any diagnosis based on coding should be accurate using the algorithms outlined, although very un-sensitive. The range of PPV values reported in other CKD validation studies has been broad (29%-100%). 15, 18 Our study used a very large population-based cohort. Only one other study has used a community based population. 18 However, Ronksley et al. looked for hospital episode data after the biochemistry identification of CKD. Therefore they were assessing whether those with CKD were being identified at their next hospital admission, not whether a prevalence cohort with CKD was identifiable equally from biochemistry or hospital episode coding. 18 This use of a three year window after biochemistry identified disease would perhaps identify patients too late for intervention, thus our method is perhaps more applicable for identifying those with disease.
We have demonstrated that those with more advanced CKD are more likely to be captured by hospital episode data, also reported by others. 18, 21 This is in keeping with the fact that at the time of this study, eGFR reporting had not been instigated in the UK and as such, the identification of CKD would be expected only in those with more advanced CKD, both by clinicians and SMR01 coders. Ronksley et al. reported that estimates of sensitivity were higher when eGFR <30 mL/min/1.73m 2 was used as the reference standard compared with using <60 mL/min/1.73m 2 . 18 Ferris et al. reported a similar pattern in in-patients. 21 Studies have reported that older age was not significantly associated with a greater likelihood of being labelled with CKD. 21 However, this was a study of inpatients, therefore the risk profile identified with biochemistry might have been different. Our finding that younger individuals with CKD were identified better on hospital episode data than older individuals has been previously reported. 18 For younger individuals, CKD is likely to be more of a significant problem than for those that are elderly with CKD with the same degree of renal impairment. It may also reflect that those with CKD at younger ages are likely to have fewer comorbidites when admitted to hospital and therefore have this recognised when discharge coding is carried out. 31 Denburg et al. 17 looked at the recording of biochemistry results at a general practice level compared to the recognition of CKD on general practice coding, which again found low sensitivity but excellent specificity and high PPV. It is unclear, however, how many of the biochemistry results had been entered into GP systems manually.
Strengths and limitations
This study has many strengths. It is one of only a few studies assessing agreement between biochemistry defined CKD that was required to be present for greater than three months compared to hospital episode data. 18, 20, 21 It is a very large population-based cohort, not limited to a specific patient group, and since ICD-10 coding is used, we might expect these findings to be potentially generalisable to other chronic diseases, eg diabetes, and across the world. The universal nature of the biochemistry service to the region ensures that those living within the region who have testing of renal function would have results available for 19 consideration, and where repeated these would be available, assisting in the identification of those with truly chronic kidney disease.
There are, however, limitations to this study. Calculating eGFR using the MDRD equation is reflective of current UK practice and thus the individuals currently identified as having CKD, however there are others outside of the UK who support the use of the CKD-EPI equation. It would be expected that both eGFR equations would identify similar individuals with CKD, particularly at more advanced stages, and it is unlikely that the results would be significantly different. 31 The use of only hospital episode data as a source of confirmatory CKD recording, although fulfilling the aim of this paper to ascertain its validity, meant that other routine sources of such data such as GP coding, were not assessed. Although this would be a useful additional source of data, it was not available to us, would require assessment in its own right, and has been explored at least at a GP biochemistry recording level before. 17 Our biochemistry definition of no-CKD was all-inclusive, including impaired eGFR (at least one eGFR <60ml/min/1.73m 2 but not sustained) and eGFR not measured. However, we performed sensitivity analyses, defining "no CKD" as those with normal eGFR only and found that this only improved PPV and worsened NPV. Sensitivity and specificity were similar. As noted previously, the recognition of CKD in the time prior to eGFR reporting (2008) was poor, and may have improved in the since then. However, this is unlikely to change the greater sensitivity of eGFR reporting over SMR01.
Implications for future research or clinical practice
As mentioned in the introduction, hospital episode data may be sufficient for acute hospital care requiring events. However, for chronic conditions, as illustrated here with CKD, the use 20 of corroborating additional data when admissions are due to another event or comorbidity may be necessary.
As demonstrated, hospital episode coding data is very specific with high PPV for the identification of individuals with CKD. This has implications for both clinical practice and future research. With clinical practice, it is insufficient to use hospital episode data alone to identify those with CKD, and access to current and historical biochemistry data is essential to identifying CKD appropriately. However, the use of hospital episode data as an additional flag is potentially useful for identifying high risk individuals. Another issue for clinical practice is patient safety, particularly with the prescribing of drugs that are either nephrotoxic or with significant renal clearance. The use of both systems of identification should improve patient safety issues related to this. This also applies to preparation for surgical, radiological and oncological procedures.
For research, we have demonstrated that biochemistry data is crucial for describing the prevalence of CKD and therefore the healthcare burden associated with it, not just the few identified through hospital episode data. Historically, CKD identified through hospital episode coding described high RRT initiation rates. However, in cohorts identified through biochemistry more recently, the rates reported have been lower. 32 Whether this is due to the severity of CKD identified being different, or due to the disease processes being different, is not clear and requires further research. There are also implications for clinical trials, in that the event rate that sample sizes are based on may differ depending on the source of CKD identification. 21 The ideal for the future would be a unifying electronic patient healthcare record containing information on previous hospital identified events, general practice and also biochemistry results, to ensure accurate and timely identification of those with CKD.
Conclusion
The findings of this study suggest that routine hospital episode data has limited value in the routine identification of individuals with CKD. However where those with CKD have been identified using hospital episode data, this information is highly specific. Other sources of routine health care data such as routine biochemistry data, including historical data, and not just that pertaining to a given event, should be available to clinicians caring for patients, and
are an important source for further research into clinical outcomes, including hospitalisations.
The most important uses of this data are for planning, surveillance, screening, and for research.
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